GeminIQ

BIIB

BIOGEN INC.
$216.01previous close on: 9/16/2026

Company Information

Company Name
BIOGEN INC.
CIK
CIK0000875045
Category
Large accelerated filer
Ticker: Exchange
BIIB: Nasdaq
Fiscal Year End
December 31
Owner Organization
03 Life Sciences
SIC
2836
SIC Description
Biological Products, (No Diagnostic Substances)
Ticker
BIIB

SEC filing data through

Insider Sentiment

Last purchase
2026-02-12
Last sale
2026-02-09
Shares purchased (TTM)
1,238
Shares sold (TTM)
18,714
Buy ratio (TTM)6.2%

Institutional Sentiment

As of
2026-03-31
Institutional shares owned
127,220,725
Shares outstanding
147,200,000
Ownership
86.43%
+5.72% Y/Y

Earnings Market Reaction

Filing date
2026-04-29
Price on filing date
—
1-month reaction
-0.32%
3-month reaction
5.97%
Drift continued5/12 (42%)
Faded / reversed7/12 (58%)
Export data

Balance Sheet

Values in millions ($)
Line item2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnTrend
Nonrelated Party1,369--250211,603--91231,605-961,686
Related Party1,369--250211,603--91231,605-961,686
Assets Current
Cash And Cash Equivalents At Carrying Value3,3833,0093,8632,7592,5982,3751,6991,9091,0741,0502,2882,618
Available For Sale Securities Debt Securities Current90080798--0---003,461
Accounts Receivable Net Current-1,342---1,405---1,664--
Inventory Net1,9492,1682,2092,2742,2742,4612,4692,5062,5172,5272,9821,334
Other Assets Current1,1681,1239178517577536746151,1651,182974896
Assets Current9,1908,9748,9377,9687,6267,4576,8317,1096,7566,8598,45410,432
Available For Sale Securities Debt Securities Noncurrent466432---0---001,208
Property Plant And Equipment Net3,0183,0553,0763,0993,1323,1813,2113,2493,2753,3103,3023,307
Operating Lease Right Of Use Asset251265331335346356380389428420461367
Intangible Assets Net Excluding Goodwill9,0549,1799,3329,4689,5859,6919,8068,2338,2858,3637,3451,776
Goodwill6,4896,4916,4916,4936,4776,4796,4866,2276,2276,2196,8085,754
Deferred Income Tax Assets Net2382933123313083249699158989291,0701,208
Other Assets Noncurrent7787517306385595616316826987457551,105
Assets29,48329,44029,20828,33028,03328,04928,31326,80426,56826,84528,19325,157
Liabilities Current
Notes Payable Current--001,749-1,7480250-500-
Debt Current-0---1,749---150--
Taxes Payable Current94115103115626548499282231257244260
Accounts Payable Current359432413408392424423355387403440445
Other Liabilities Current2,5472,8032,7742,6612,5312,8082,7552,4722,3552,6243,8382,481
Liabilities Current2,9993,3493,2903,1845,2975,5295,4253,1083,2233,4345,0223,187
Long Term Debt6,2896,2876,2856,2844,5494,5474,5466,2926,2906,7886,7866,285
Deferred Income Tax Liabilities Net484508358118133191882591658642728144
Operating Lease Liability Noncurrent273290305311323335357368407400429304
Other Liabilities Noncurrent787749762800752732744557777781748777
Liabilities10,83111,18311,00010,69611,05411,33311,95410,91511,35512,04513,71410,696
Stockholders Equity
Preferred Stock Value Outstanding-0---0---0--
Common Stock Value Outstanding-0---0---0--
Preferred Stock Value0-000-000-00
Common Stock Value0-000-000-00
Additional Paid In Capital897863798714630569489408330303242171
Accumulated Other Comprehensive Income Loss Net Of Tax-140-182-215-238-175-136-146-146-161-154-159-173
Retained Earnings Accumulated Deficit20,87220,55320,60220,13519,50019,26018,99318,60518,02117,62817,37817,446
Treasury Stock Value-2,977-2,977-2,977-2,977-2,977-2,977-2,977-2,977-2,977-2,977-2,977-2,977
Stockholders Equity18,65218,25718,20817,63416,97916,71616,35915,88915,21314,79914,48014,461
Liabilities And Stockholders Equity29,48329,44029,20828,33028,03328,04928,31326,80426,56826,84528,19325,157
Allowance For Doubtful Accounts Receivable Current3322222222--
Minority Interest---------0-4-6
Preferred Stock Par Or Stated Value Per Share0.000.000.000.000.000.000.000.000.000.00--
Common Stock Par Or Stated Value Per Share0.000.000.000.000.000.000.000.000.000.00--
Treasury Stock Common Shares-24---24---24--

Select a line item above to chart it.

Recent filings

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial

BIOGEN INC. (BIIB) — SEC Financial Statements & Analysis

BIOGEN INC. (BIIB) is a biological products, (no diagnostic substances) company, incorporated in DE. BIOGEN INC. trades on Nasdaq as: BIIB. BIOGEN INC. (BIIB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-04-29. Based on that filing, BIOGEN INC. carries a market cap of $26.99B, a P/E ratio of 19.67x, a P/B ratio of 1.45x, a P/S ratio of 2.72x, an enterprise value of $29.89B, and an EV/EBITDA multiple of 12.33x. On profitability, it posts a gross margin of 75.49%, an operating margin of 16.33%, a net margin of 13.81%, a Return on Equity (ROE) of 7.70%, a Return on Assets (ROA) of 4.77%, and a Return on Invested Capital (ROIC) of 6.44%. Per share, it reports EPS of $9.32, diluted EPS of $9.24, free cash flow per share of $16.46, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 1.23% year-over-year, net income growth of -7.26% year-over-year, and EPS growth of -7.95% year-over-year. On the balance sheet, it maintains a current ratio of 3.06x, a quick ratio of 2.41x, working capital of $6.19B, a debt-to-equity ratio of 0.58x, a debt ratio of 0.37, free cash flow of $2.42B (TTM), and net debt of $2.91B. Figures sourced from SEC EDGAR.

Market Cap
$26.99B
P/E TTM
19.67x
EPS TTM
$9.32
P/B TTM
1.45x
ROE TTM
7.70%
ROA TTM
4.77%
Debt To Equity
0.58x
Free Cash Flow TTM
$2.42B
Net Revenue TTM Growth 1Y
1.23%

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is BIOGEN INC. in?

BIOGEN INC. (BIIB) operates in the Biological Products, (No Diagnostic Substances) industry.

What exchange does BIIB trade on?

BIOGEN INC. (BIIB) trades on the Nasdaq.

Where is BIOGEN INC. incorporated?

BIOGEN INC. is incorporated in DE.

When was BIOGEN INC. (BIIB)'s most recent SEC filing?

BIOGEN INC. (BIIB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-04-29.

What is BIIB's market cap?

BIOGEN INC. (BIIB) has a market capitalization of $26.99B as of 2026-03-31.

What is BIIB's P/E ratio?

BIOGEN INC. (BIIB)'s trailing twelve month P/E ratio is 19.67x as of 2026-03-31.

What is BIIB's EPS (earnings per share)?

BIOGEN INC. (BIIB)'s trailing twelve month EPS is $9.32 as of 2026-03-31.

What is BIIB's ROE (return on equity)?

BIOGEN INC. (BIIB)'s trailing twelve month Return on Equity (ROE) is 7.70% as of 2026-03-31.

What is BIIB's ROA (return on assets)?

BIOGEN INC. (BIIB)'s trailing twelve month Return on Assets (ROA) is 4.77% as of 2026-03-31.

What is BIIB's ROIC (return on invested capital)?

BIOGEN INC. (BIIB)'s trailing twelve month Return on Invested Capital (ROIC) is 6.44% as of 2026-03-31.

What is BIIB's EV/EBITDA?

BIOGEN INC. (BIIB)'s trailing twelve month EV/EBITDA is 12.33x as of 2026-03-31.

Wall Street's data.
Main Street's price.

Start 7-day free trial